Results missed on top line and EBITDA and company remains cautious on its outlook. We expect to significantly cut our estimates, but will await more details in the analyst meeting. We put our rating and TP under review.
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Results missed on top line and EBITDA and company remains cautious on its outlook. We expect to significantly cut our estimates, but will await more details in the analyst meeting. We put our rating and TP under review.
